It is possible that targeting a combination of targets, such as CLL-1, CD33 and CD123 might be most effective in JMML even though CD33 and CD123 did not pass the filters in our bioinformatic pipeline. The gene discussed is CD33; the disease is juvenile myelomonocytic leukemia.